-
Something wrong with this record ?
The Combined Use of Imaging Approaches to Assess Drug Release from Multicomponent Solid Dispersions
K. Punčochová, AV. Ewing, M. Gajdošová, T. Pekárek, J. Beránek, SG. Kazarian, F. Štěpánek,
Language English Country United States
Document type Journal Article
NLK
ProQuest Central
from 1997-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2010-01-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 1997-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-01-01 to 1 year ago
- MeSH
- Chemistry, Pharmaceutical methods MeSH
- Crystallization MeSH
- Magnetic Resonance Imaging methods MeSH
- Morpholines chemistry MeSH
- Drug Carriers chemistry MeSH
- Polyethylene Glycols chemistry MeSH
- Polymers chemistry MeSH
- Polyvinyls chemistry MeSH
- Pyrrolidines chemistry MeSH
- Solubility MeSH
- Spectroscopy, Fourier Transform Infrared methods MeSH
- Drug Liberation MeSH
- Water chemistry MeSH
- Publication type
- Journal Article MeSH
PURPOSE: Imaging methods were used as tools to provide an understanding of phenomena that occur during dissolution experiments, and ultimately to select the best ratio of two polymers in a matrix in terms of enhancement of the dissolution rate and prevention of crystallization during dissolution. METHODS: Magnetic resonance imaging, ATR-FTIR spectroscopic imaging and Raman mapping have been used to study the release mechanism of a poorly water soluble drug, aprepitant, from multicomponent amorphous solid dispersions. Solid dispersions were prepared based on the combination of two selected polymers - Soluplus, as a solubilizer, and PVP, as a dissolution enhancer. Formulations were prepared in a ratio of Soluplus:PVP 1:10, 1:5, 1:3, and 1:1, in order to obtain favorable properties of the polymer carrier. RESULTS: The crystallization of aprepitant during dissolution has occurred to a varying degree in the polymer ratios 1:10, 1:5, and 1:3, but the increasing presence of Soluplus in the formulation delayed the onset of crystallization. The Soluplus:PVP 1:1 solid dispersion proved to be the best matrix studied, combining the abilities of both polymers in a synergistic manner. CONCLUSIONS: Aprepitant dissolution rate has been significantly enhanced. This study highlights the benefits of combining imaging methods in order to understand the release process.
Department of Chemical Engineering Imperial College London South Kensington Campus London SW7 2AZ UK
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18017074
- 003
- CZ-PrNML
- 005
- 20180521090604.0
- 007
- ta
- 008
- 180515s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11095-016-2018-x $2 doi
- 035 __
- $a (PubMed)27573574
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Punčochová, Kateřina $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Prague 6, Czech Republic. Zentiva, k.s, U Kabelovny 130, Prague 10, Czech Republic.
- 245 14
- $a The Combined Use of Imaging Approaches to Assess Drug Release from Multicomponent Solid Dispersions / $c K. Punčochová, AV. Ewing, M. Gajdošová, T. Pekárek, J. Beránek, SG. Kazarian, F. Štěpánek,
- 520 9_
- $a PURPOSE: Imaging methods were used as tools to provide an understanding of phenomena that occur during dissolution experiments, and ultimately to select the best ratio of two polymers in a matrix in terms of enhancement of the dissolution rate and prevention of crystallization during dissolution. METHODS: Magnetic resonance imaging, ATR-FTIR spectroscopic imaging and Raman mapping have been used to study the release mechanism of a poorly water soluble drug, aprepitant, from multicomponent amorphous solid dispersions. Solid dispersions were prepared based on the combination of two selected polymers - Soluplus, as a solubilizer, and PVP, as a dissolution enhancer. Formulations were prepared in a ratio of Soluplus:PVP 1:10, 1:5, 1:3, and 1:1, in order to obtain favorable properties of the polymer carrier. RESULTS: The crystallization of aprepitant during dissolution has occurred to a varying degree in the polymer ratios 1:10, 1:5, and 1:3, but the increasing presence of Soluplus in the formulation delayed the onset of crystallization. The Soluplus:PVP 1:1 solid dispersion proved to be the best matrix studied, combining the abilities of both polymers in a synergistic manner. CONCLUSIONS: Aprepitant dissolution rate has been significantly enhanced. This study highlights the benefits of combining imaging methods in order to understand the release process.
- 650 _2
- $a farmaceutická chemie $x metody $7 D002626
- 650 _2
- $a krystalizace $7 D003460
- 650 _2
- $a nosiče léků $x chemie $7 D004337
- 650 _2
- $a uvolňování léčiv $7 D065546
- 650 _2
- $a magnetická rezonanční tomografie $x metody $7 D008279
- 650 _2
- $a morfoliny $x chemie $7 D009025
- 650 _2
- $a polyethylenglykoly $x chemie $7 D011092
- 650 _2
- $a polymery $x chemie $7 D011108
- 650 _2
- $a polyvinyly $x chemie $7 D011145
- 650 _2
- $a pyrrolidiny $x chemie $7 D011759
- 650 _2
- $a rozpustnost $7 D012995
- 650 _2
- $a spektroskopie infračervená s Fourierovou transformací $x metody $7 D017550
- 650 _2
- $a voda $x chemie $7 D014867
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Ewing, Andrew V $u Department of Chemical Engineering, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK.
- 700 1_
- $a Gajdošová, Michaela $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Prague 6, Czech Republic.
- 700 1_
- $a Pekárek, Tomáš $u Zentiva, k.s, U Kabelovny 130, Prague 10, Czech Republic.
- 700 1_
- $a Beránek, Josef $u Zentiva, k.s, U Kabelovny 130, Prague 10, Czech Republic.
- 700 1_
- $a Kazarian, Sergei G $u Department of Chemical Engineering, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK. s.kazarian@imperial.ac.uk.
- 700 1_
- $a Štěpánek, František $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Prague 6, Czech Republic. Frantisek.Stepanek@vscht.cz.
- 773 0_
- $w MED00003779 $t Pharmaceutical research $x 1573-904X $g Roč. 34, č. 5 (2017), s. 990-1001
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27573574 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180521090746 $b ABA008
- 999 __
- $a ok $b bmc $g 1300698 $s 1013914
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 34 $c 5 $d 990-1001 $e 20160829 $i 1573-904X $m Pharmaceutical research $n Pharm Res $x MED00003779
- LZP __
- $a Pubmed-20180515